Holen Sie sich die Stockscreener-App
12.07
1.26%
0.15
Vorhandelsmarkt:
12.44
0.37
+3.07%
Schlusskurs vom Vortag:
$11.92
Offen:
$11.77
24-Stunden-Volumen:
3.81M
Relative Volume:
1.48
Marktkapitalisierung:
$3.80B
Einnahmen:
$3.02B
Nettoeinkommen (Verlust:
$127.93M
KGV:
54.54
EPS:
0.2213
Netto-Cashflow:
$225.64M
1W Leistung:
-2.90%
1M Leistung:
-17.67%
6M Leistung:
+24.30%
1J Leistung:
+35.77%
1-Tages-Spanne:
$11.71
$12.13
1-Wochen-Bereich:
$11.71
$12.54
52-Wochen-Spanne:
$6.685
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.07 | 3.80B | 3.02B | 127.93M | 225.64M | 0.2213 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Amneal Pharmaceuticals stock gains momentum as Truist raises target to $17 amid analyst optimism - AD HOC NEWS
Oliver Luxxe Assets LLC Purchases New Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) added to S&P SmallCap 600 Index, boosting investor visibility - MSN
Aug Selloffs: Whats the fair value of Amneal Pharmaceuticals Inc stock2026 Price Momentum & Technical Confirmation Trade Alerts - baoquankhu1.vn
How Amneal’s Margin-Focused 2026 Outlook and 2025 Results Could Impact Amneal Pharmaceuticals (AMRX) Investors - simplywall.st
AMRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? - MSN
Hydroxychloroquine Market Is Booming So Rapidly | Sanofi and Amneal Pharmaceuticals, LLC - openPR.com
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Strong 2025 Results And 2026 Growth Guidance - Sahm
Stock Recap: Is Amneal Pharmaceuticals Inc in a long term uptrend2026 Fundamental Recap & Long-Term Investment Growth Plans - baoquankhu1.vn
Aug Analyst Calls: What are the future prospects of Amneal Pharmaceuticals IncPortfolio Gains Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Retail Surge: Will Amneal Pharmaceuticals Inc benefit from green energy policies2026 Winners & Losers & Community Verified Swing Trade Signals - baoquankhu1.vn
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX) - Seeking Alpha
Algert Global LLC Cuts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory - MSN
Capula Management Ltd Buys New Shares in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
AMRX PE Ratio & Valuation, Is AMRX Overvalued - Intellectia AI
Is Amneal Pharmaceuticals (AMRX) Pricing Reflect Its DCF Gap And Recent Share Slide - Yahoo Finance
Fed Meeting: Does Amneal Pharmaceuticals Inc stock have upside surprise potential2026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 5.5%Here's What Happened - MarketBeat
Amneal Pharmaceuticals Inc (AMRX) Shares Gap Down to $12.73 on M - GuruFocus
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment - Yahoo Finance
What Amneal Pharmaceuticals (AMRX)'s Return to Profitability and 2026 Guidance Means For Shareholders - simplywall.st
Amneal Pharmaceuticals Conference: “Amneal 2.0” Targets 2026 Growth in Biosimilars, CREXONT and AvKARE Shift - MarketBeat
Amneal (AMRX) Stock Analysis 2026: Strong Gains vs. Future Growth ConcernsNews and Statistics - IndexBox
Shorts Report: Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdForecast Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead - Finviz
AMRX: Biosimilars and specialty launches fuel growth, with profitability and global expansion accelerating - TradingView
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Best Value Stocks to Buy for March 9th - The Globe and Mail
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - MSN
Trade Report: Will Amneal Pharmaceuticals Inc benefit from current market trends2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
Citigroup Inc. Purchases 101,166 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by Quantbot Technologies LP - MarketBeat
Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Amneal to Participate in Upcoming Investor Conference - National Today
Amneal (NYSE: AMRX) Co-CEO settles RSUs, withholds stock to cover taxes - Stock Titan
Amneal (AMRX) Co-CEO gains shares via RSU and performance awards - Stock Titan
Amneal (AMRX) EVP nets stock from RSU vesting and tax withholdings - Stock Titan
AMRX SEC FilingsAmneal Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Amneal (AMRX) Co-CEO Chintu Patel gets major RSU and PSU grants - Stock Titan
Amneal (AMRX) Co-CEO awarded time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) EVP awarded time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) CFO granted time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP - Stock Titan
Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs - Stock Titan
AMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc. - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring A 19% Upside Potential - DirectorsTalk Interviews
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Drops By 16.4% - MarketBeat
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):